Title:
Cladribine Dosing Plan to Treat Multiple Sclerosis
Document Type and Number:
Japanese Patent JP6290962
Kind Code:
B2
Abstract:
The present invention is related to a Cladribine dosage regimen for use in the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the Cladribine is orally administered and wherein re-treatments are possible.
Inventors:
Derca, Giampiero
Arnie
Munafo, Allen
Lopez-Bresnahan, Maria
Arnie
Munafo, Allen
Lopez-Bresnahan, Maria
Application Number:
JP2016078293A
Publication Date:
March 07, 2018
Filing Date:
April 08, 2016
Export Citation:
Assignee:
Merck Serono Society Anonym
International Classes:
A61K31/7076; A61K9/20; A61K9/48; A61K38/28; A61P25/28
Foreign References:
| WO2004075903A1 | ||||
| WO2004016263A1 |
Other References:
GRIEB,P. et al,Archivum immunologiae et therapiae experimentalis,1995年,Vol.43, No.5-6,p.323-7
STELMASIAK,Z. et al,Medical Science Monitor,1998年,Vol.4, No.1,p.4-8
新・薬剤学総論(改訂第3版),株式会社南江堂,1987年,pp.240-247
STELMASIAK,Z. et al,Medical Science Monitor,1998年,Vol.4, No.1,p.4-8
新・薬剤学総論(改訂第3版),株式会社南江堂,1987年,pp.240-247
Attorney, Agent or Firm:
Atsushi Aoki
Takashi Ishida
Fukumoto product
Tetsuji Koga
Yoichi Watanabe
Ryotaro Takei
Takahide Sasaki
Takashi Ishida
Fukumoto product
Tetsuji Koga
Yoichi Watanabe
Ryotaro Takei
Takahide Sasaki